Stock listing

Lang & Schwarz:A2PEFW CStone Pharmaceuticals Aktie

German listing (Lang & Schwarz) of CStone Pharmaceuticals · home listing HKEX:2616

Follow CStone Pharmaceuticals into a list and get an email when it puts out news.

Home listing price · HKEX:2616

$5.68 HKD -0.21 (-3.6%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, HKEX:2616

Past year -5.0% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$5.60 – $6.00 HKDNov 20, 2026
Volume
13.97M sharesNov 20, 2026
Market cap
$9.05B HKDAt the close on Nov 20, 2026 · price × 1.59B shares outstanding
52-week range
$4.01 – $10.41 HKDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$52.79M HKDMedian day 7.85M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
CStone Pharmaceuticals logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
HKEX:2616 · Home$5.68 HKD-0.215 (-3.6%)13,966,500$6.00$6.00$5.595$5.895Close on Nov 20, 2026
OTC:CSPHF$0.75 USD+0.061 (+8.8%)201$0.75$0.75$0.75$0.689Close on Nov 17, 2026
Frankfurt:PH4€0.638 EUR-0.025 (-3.8%)—€0.639€0.639€0.638€0.663Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · HKEX:2616 · HKD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$5.68-0.215-3.6%$6.00$6.00$5.59513,966,500
$5.895+0.435+8.0%$5.46$6.095$5.31516,050,954
$5.46+0.305+5.9%$5.155$5.49$5.045,428,075
$5.155-0.05-1.0%$5.11$5.23$5.015,260,500
$5.205-0.26-4.8%$5.425$5.47$5.183,988,000
$5.465-0.015-0.3%$5.48$5.53$5.324,630,000
$5.480.000.0%$5.475$5.54$5.373,334,000
$5.48+0.07+1.3%$5.41$5.575$5.355,141,500
$5.41+0.065+1.2%$5.30$5.61$5.304,312,740
$5.345-0.29-5.1%$5.20$5.625$5.206,723,479
$5.635+0.225+4.2%$5.53$5.75$5.43512,197,500
$5.41+0.565+11.7%$4.83$5.41$4.8259,091,382
$4.845-0.105-2.1%$4.87$4.96$4.6759,155,521
$4.95+0.01+0.2%$5.00$5.105$4.795,949,000
$4.94+0.205+4.3%$4.69$5.165$4.6059,052,164
$4.735-0.02-0.4%$4.755$4.88$4.713,955,642
$4.755+0.185+4.0%$4.615$4.875$4.6155,297,612
$4.57-0.355-7.2%$4.99$4.99$4.537,890,500
$4.925+0.055+1.1%$5.015$5.215$4.808,386,448
$4.87+0.17+3.6%$4.75$4.875$4.5755,146,588
$4.70-0.34-6.7%$5.03$5.095$4.6258,727,000
$5.04-0.045-0.9%$5.13$5.27$5.0253,213,000
$5.085+0.115+2.3%$5.105$5.115$4.8853,086,408
$4.97+0.275+5.9%$4.695$5.06$4.6956,431,998
$4.695-0.085-1.8%$4.80$4.815$4.6357,495,000
$4.78-0.20-4.0%$4.98$4.995$4.7758,276,000
$4.98-0.02-0.4%$4.99$5.09$4.7857,076,767
$5.00-0.09-1.8%$5.14$5.295$5.007,109,756
$5.09-0.15-2.9%$5.26$5.29$4.949,959,270
$5.24-0.545-9.4%$5.745$5.79$5.2310,841,500
$5.785-0.065-1.1%$5.845$5.845$5.561,400,500
$5.85+0.18+3.2%$5.67$5.915$5.672,786,269
$5.67+0.015+0.3%$5.66$5.73$5.5851,231,500
$5.655-0.245-4.2%$5.895$5.895$5.424,100,584
$5.90+0.34+6.1%$5.56$5.95$5.5457,938,130
$5.56+0.42+8.2%$5.15$5.64$5.129,457,000
$5.14-0.195-3.7%$5.475$5.475$5.047,553,000
$5.335-0.04-0.7%$5.39$5.555$5.251,732,500
$5.375-0.405-7.0%$5.77$5.77$5.377,806,000
$5.78+0.09+1.6%$5.75$5.875$5.6955,608,848
$5.69+0.04+0.7%$5.63$5.72$5.515,282,000
$5.65+0.315+5.9%$5.38$5.82$5.3811,699,374
$5.335-0.045-0.8%$5.39$5.60$5.21515,649,300
$5.38+0.185+3.6%$5.195$5.44$5.0616,464,129
$5.195-0.75-12.6%$5.95$5.95$5.12520,548,381
$5.945-0.03-0.5%$6.02$6.145$5.82525,034,500
$5.975+0.19+3.3%$5.785$6.10$5.5813,259,000
$5.785-0.295-4.9%$5.99$5.99$5.55525,003,500
$6.08-0.085-1.4%$6.165$6.36$5.9722,335,500
$6.165-0.01-0.2%$6.24$6.295$6.0024,703,000
$6.175+0.105+1.7%$6.07$6.495$5.89520,020,500
$6.07-0.12-1.9%$6.48$6.58$5.8538,957,301
$6.19+0.01+0.2%$6.20$6.495$6.198,773,345
$6.180.000.0%$6.28$6.35$6.0155,589,302
$6.18+0.475+8.3%$5.755$6.25$5.7359,929,500
$5.705-0.045-0.8%$5.75$5.86$5.605,200,000
$5.75-0.14-2.4%$5.89$5.89$5.5010,319,297
$5.89-0.48-7.5%$6.55$6.65$5.7313,034,000
$6.37+0.44+7.4%$5.935$6.37$5.8410,074,000
$5.93+0.09+1.5%$5.945$6.155$5.8458,285,000
$5.84+0.29+5.2%$5.55$5.955$5.3556,002,000
$5.55+0.165+3.1%$5.59$5.75$5.406,801,000
$5.385-0.065-1.2%$5.50$5.545$5.255,437,000
$5.45+0.33+6.4%$5.30$5.715$5.229,548,500
Ticker
Lang & Schwarz:A2PEFW
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Lang & Schwarz
Currency
EUR

What changed lately

Latest news

Interim report 2026

Sep 28, 2026

Closed $5.56 (+8.2%) on Sep 29, 2026

All CStone Pharmaceuticals news

CStone Pharmaceuticals on 6ix

Sector
Health care
Industry
Biotechnology
News releases
16 in the last 12 months · 33 in all · newest Nov 20, 2026 · oldest 2024
Decks
23 decks · latest Aug 28, 2026

Where CStone Pharmaceuticals is listed

ListingExchangeCountryCurrency
HKEX:2616 基石藥業 · Home listingHKEXHong KongHKD
gettex:PH4gettexGermanyEUR
LS Exchange:A2PEFWLS ExchangeGermanyEUR
Lang & Schwarz:A2PEFW · This pageLang & SchwarzGermanyEUR
OTC:CSPHFOTCUnited StatesUSD
Stuttgart:PH4StuttgartGermanyEUR
Dusseldorf:PH4DusseldorfGermanyEUR
Frankfurt:PH4FrankfurtGermanyEUR
Munich:PH4MunichGermanyEUR
Tradegate:PH4TradegateGermanyEUR

Valuation

EV/sales 24.1× against a median of 36.1×: 3rd lowest of 6 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026

Enterprise value
$7.64B HKD
P/E
Loss
EV/sales
24.1×
EV/EBITDA
Negative EBITDA
Price/book
6.0×
Gross margin
19.0%
Operating margin
−160.5%
Net margin
−162.1%
Debt to equity
0.3×
Beta
No index for this market yet

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
CStone Pharmaceuticals · HKEX:2616US$1.16BUS$974.6Mn/a24.1×n/a6.0×−162.1%0.3×n/a
Taysha Gene Therapies, Inc. · NASDAQ:TSHAUS$1.21BUS$837.4Mn/a153×n/a3.4×n/a0.1×1.69
Mineralys Therapeutics, Inc. · NASDAQ:MLYSUS$1.21BUS$585.1Mn/an/an/a2.4×n/a0.0×1.39
GH Research PLC · NASDAQ:GHRSUS$1.20BUS$841.0Mn/an/an/a3.4×n/a0.0×1.28
Vor Biopharma Inc. · NASDAQ:VORUS$1.18BUS$697.4M0.9×n/an/an/an/an/a1.25
Staidson (Beijing) Biopharmaceuticals Co. Ltd. Class A · SZSE:300204US$1.17BUS$1.01Bn/a36.1×n/a3.9×−53.3%0.0×n/a
OPKO Health, Inc. · NASDAQ:OPKUS$1.17BUS$1.26Bn/a2.5×n/a1.0×−29.5%0.4×0.90
D&D Pharmatech Co., Ltd. · KRX:347850US$1.15BUS$1.12Bn/a549×n/a11.5×−785.5%0.8×n/a
Structure Therapeutics, Inc. · NASDAQ:GPCRUS$1.15B−US$82.92Mn/an/an/a0.9×n/a0.0×1.38
COMPASS Pathways Plc · NASDAQ:CMPSUS$1.14BUS$747.8Mn/an/an/a8.0×n/a0.4×1.65
Ascentage Pharma Group International · HKEX:6855US$1.11BUS$1.14Bn/a13.6×n/a13.3×−216.5%3.8×n/a
Median of the othersUS$1.17BUS$839.2M0.9×36.1×3.4×−134.9%0.1×1.38

Forecasts

Analysts' consensus from EODHD, read Nov 11, 2026. Not 6ix's view and not investment advice.

Price target
15.60 HKD · Analysts' mean
EPS, year to Dec 2026
-0.29 · 1 analyst
Revenue, year to Dec 2026
423.2M · 2 analysts

Team and board

OfficerRole
Jason YangChief Executive Officer, President of R&D
Weicong NiChief Financial Officer and Company Secretary
Yinghua ZhangChief Operating Officer
Michael ChoiChief Business and Strategy Officer
Qingmei ShiChief Medical Officer
Qinzhou QiHead of R&D Management and Chief of Staff to the CEO
Yujuan LaHead of Product Development

Events

QuarterResultsShare move
Q2 2025Aug 14, 2025 · Before open+0.4%
Quarter to Mar 31, 2025Apr 28, 2025+0.3%
Q4 2024Mar 27, 2025−1.5%
Q4 2022Mar 15, 2023 · Before open+7.4%

Open Events

Decks

DeckKindSlidesDate
H1 2026 Earnings PresentationEarnings61 slidesAug 28, 2026
FY2025 Earnings PresentationEarnings43 slidesMar 27, 2026
H1 2025 Earnings PresentationEarnings41 slidesAug 15, 2025
FY2024 Earnings PresentationEarnings65 slidesMar 28, 2025
Investor Presentation (November 2024)Investor deck44 slidesNovember 2024
H1 2024 Earnings PresentationEarnings40 slidesAug 26, 2024
FY2023 Earnings PresentationEarnings38 slidesMar 28, 2024
FY2023 Earnings PresentationEarnings38 slidesMar 28, 2024
Corporate Update (December 2023)Corporate update34 slidesDec 20, 2023
H1 2023 Earnings PresentationEarnings26 slidesAug 16, 2023
All 23 decks
DeckKindSlidesDate
FY2022 Earnings PresentationEarnings33 slidesMar 16, 2023
FY2021 Earnings PresentationEarnings34 slidesJun 1, 2022
Investor Presentation (May 2022)Investor deck35 slidesMay 2022
Investor Presentation (April 2022)Investor deck35 slidesApril 2022
Investor Presentation (February 2022)Investor deck35 slidesFebruary 2022
Investor Presentation (January 2022)Investor deck35 slidesJanuary 2022
Investor Presentation (November 2021)Investor deck34 slidesNovember 2021
H1 2021 Earnings PresentationEarnings31 slidesAug 27, 2021
Investor Presentation (June 2021)Investor deck33 slidesJune 2021
Investor Presentation (June 2021)Investor deck34 slidesJune 2021
Investor Presentation (March 2021)Investor deck32 slidesMarch 2021
Investor Presentation (September 2020)Investor deck36 slidesSeptember 2020
Investor Presentation (April 2020)Investor deck37 slidesApril 2020

Open Decks

Financials

Annual, in CNY

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue269.6M407.2M463.8M481.4M243.7M1.04B012.6M10.3M0
Cost of revenue218.3M167.1M159.5M203.0M106.8M241.4M000
Gross profit51.2M240.2M304.3M278.4M136.9M797.4M12.6M10.3M0
Research and development311.5M134.7M527.8M614.2M1.30B1.40B1.40B850.2M213.4M247.1M
Selling, general and administrative87.3M33.2M48.7M63.2M109.2M86.7M338.6M191.0M39.3M15.1M
Operating income-432.6M-91.7M-605.6M-912.1M-1.83B-1.09B-1.74B-1.03B-242.5M-262.2M
Depreciation and amortization44.0M49.8M58.2M44.5M22.7M14.8M11.6M5.27M823.4K69.0K
EBITDA-388.6M-41.9M-547.4M-867.6M-1.81B-1.08B-1.73B-1.02B-241.7M-262.1M
Interest expense12.9M15.2M11.8M8.48M2.24M1.32M303.0K745.6M60.0K240.0K
Income before tax-423.9M-91.2M-367.2M-902.7M-1.92B-1.22B-2.31B-1.79B-342.5M-253.0M
Income tax13.1M61.9M67.3M-1.10M748.4M-734.0M00
Net income-437.0M-91.2M-367.2M-902.7M-1.92B-1.22B-2.31B-1.75B-308.9M-246.1M
Earnings per share, basic-0.31-0.07-0.29-0.77-1.65-1.04-2.34-1.77-0.31-0.25

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents754.0M387.9M996.7M558.7M742.7M3.02B1.13B701.3M83.4M59.5M
Short-term investments165.1M285.0M51.9M483.4M983.6M369.0M1.62B856.6M454.3M752.4M
Receivables33.8M130.9M172.4M77.1M117.6M0760.0K
Inventory116.9M286.1M108.8M22.2M61.4M0
Current assets1.11B1.09B1.33B1.25B1.96B3.57B2.89B1.60B545.3M824.8M
Property, plant and equipment130.5M153.4M206.6M182.8M102.0M18.7M14.5M15.5M1.03M
Total assets1.36B1.39B1.66B1.64B2.27B3.76B2.95B1.63B564.3M826.1M
Accounts payable77.2M338.0M246.4M290.4M414.3M28.0M37.3M4.56M302.0K
Current liabilities510.4M682.0M850.3M946.5M932.9M727.0M458.0M1.11B113.2M59.2M
Long-term debt156.5M257.4M213.0M219.0M115.8M54.3M
Total debt348.7M356.0M363.4M286.3M174.2M75.2M1.62B
Total liabilities741.6M1.03B1.21B1.19B1.06B808.3M469.1M1.12B113.2M59.2M
Shareholders' equity617.0M363.9M456.8M449.3M1.21B2.95B2.48B515.3M426.3M712.7M
Shares outstanding1.39B1.28B1.26B1.17B1.17B1.17B984.5M984.1M984.1M984.1M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-327.7M-343.2M-588.8M-612.5M-1.48B-508.1M-1.08B-791.1M-240.2M-213.0M
Capital spending00-65.0M-101.8M-149.1M-71.4M-10.4M-7.91M-12.5M-1.11M
Free cash flow-327.7M-343.2M-653.9M-714.3M-1.63B-579.5M-1.09B-799.0M-252.7M-214.1M
Cash from investing134.0M-247.7M619.6M365.1M-826.6M1.18B-658.9M-377.7M268.3M-753.5M
Cash from financing577.8M-12.9M388.4M28.5M92.3M1.39B2.09B1.66B-300.0K1.01B
Share buybacks74.0K341.8M2.53M16.8M-21.8M2.20B1.66B0706.5M
Change in cash365.8M-608.7M438.0M-184.0M-2.28B1.90B425.1M617.9M23.9M59.5M

Open Financials

Filings

Open Filings

Cap table

Built by 6ix from CStone Pharmaceuticals’ releases

Common shares
1,594,112,329
Fully diluted
1,594,112,329

Fully diluted

LineShares
Common shares1,594,112,329

Share count over time

CountShares
Nov 22, 20261,594,112,329

Open Cap table

Shareholders

Register

HolderSharesOf the companyAs of
WuXi Healthcare Management, LLC173M11.8%Aug 20, 2025
WuXi Healthcare Ventures II, L.P.173M11.8%Aug 20, 2025
Pfizer Inc.116M7.9%Jul 16, 2025
HHLR Advisors, Ltd.88.7M5.6%Apr 22, 2026
Yang Jianxin84.8M5.3%Oct 26, 2026

Funds

HolderSharesValueChangeAs of
Vanguard Total International Stock Index Fund18.2MUS$10M+1.91MJul 31, 2026
Vanguard Emerging Markets Stock Index Fund17.3MUS$9.52M+1.79MJul 31, 2026
iShares Core MSCI Emerging Markets ETF14.3MUS$14.7M+806KMay 31, 2026
Vanguard Ftse All-World Ex-Us Small-Cap Index Fund5.25MUS$2.89M+1.1MJul 31, 2026
State Street(R) SPDR(R) Portfolio Emerging Markets ETF1.41MUS$844K−26,500Jun 30, 2026
iShares Core MSCI Total International Stock ETF921KUS$507KNewJul 31, 2026
Vanguard Total World Stock Index Fund879KUS$484KNo changeJul 31, 2026
College Retirement Equities Fund - Total Global Stock Account687KUS$414KNo changeJun 30, 2026
Fidelity Total International Index Fund620KUS$341K−5,000Jul 31, 2026
State Street(R) SPDR(R) S&P(R) Emerging Markets Small Cap ETF588KUS$353K−42,000Jun 30, 2026
All 16 holders
HolderSharesValueChangeAs of
iShares MSCI China Small-Cap ETF450KUS$462K−144KMay 31, 2026
iShares MSCI Emerging Markets Small-Cap ETF241KUS$248KNewMay 31, 2026
State Street Global All Cap Equity ex-U.S. Index Portfolio229KUS$137KNo changeJun 30, 2026
State Street(R) SPDR(R) S&P(R) China ETF135KUS$81,082−6,000Jun 30, 2026
State Street(R) SPDR(R) S&P(R) Emerging Asia Pacific ETF34,000US$20,421+2,000Jun 30, 2026
FlexShares Morningstar Emerging Markets Factor Tilt Index Fund22,500US$12,395No changeJul 31, 2026

Insider trades

InsiderTradeSharesPriceValueDate
Yang Jianxin
Director or chief executive
Buy291,500HKD 5.63HKD 1.64MSep 22, 2026
Yang Jianxin
Director or chief executive
Buy72,000HKD 5.42HKD 391KSep 18, 2026
Yang Jianxin
Director or chief executive
Buy132,500HKD 5.24HKD 694KSep 17, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Jason YangChief Executive Officer, President of R&D · Since at least Aug 27, 2026
Michael ChoiChief Business and Strategy Officer · Since at least Nov 5, 2026
Qingmei ShiChief Medical Officer · Since at least Feb 23, 2026
Qinzhou QiHead of R&D Management and Chief of Staff to the CEO · Since at least Nov 5, 2026
Weicong NiChief Financial Officer and Company Secretary · Since at least Nov 5, 2026
Yinghua ZhangChief Operating Officer · Since at least Nov 5, 2026
Yujuan LaHead of Product Development · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about CStone Pharmaceuticals.